- Home
- PLRX vs AUTL Comparison
PLRX vs AUTL Comparison
Compare PLRX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLRX | AUTL |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.3M | 433.8M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PLRX | AUTL |
|---|---|---|
| Price | $1.22 | $1.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | $3.79 | ★ $8.33 |
| AVG Volume (30 Days) | 1.9M | ★ 2.5M |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $51,128,000.00 |
| Revenue This Year | N/A | $658.11 |
| Revenue Next Year | N/A | $91.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 406.67 |
| 52 Week Low | $1.10 | $1.11 |
| 52 Week High | $14.26 | $2.80 |
Technical Indicators
Market Signals| Indicator | PLRX | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 36.77 | 57.88 |
| Support Level | $1.20 | $1.63 |
| Resistance Level | $1.27 | $1.79 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 20.00 | 59.09 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.